| Outcome Measures: |
Primary: Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug, A summary of AEs and SAEs, AE leading to study discontinuation, AE severity and relation with study drug will be reported in the reported adverse events module, From Baseline to Day 57.|The number of participants with changes of laboratory tests blood routine, urine routine, blood biochemistry, coagulation function, From Baseline to Day 57|The changes ECG examination assessed by PR, R-R, QRS and QTcF, 12-lead electrocardiogram (ECG) parameters, From Baseline to Day 57|The changes in Blood pressure, Vital signs, From Baseline to Day 57|Pulse rate, Vital signs, From Baseline to Day 57|Respiratory rate, Vital signs, From Baseline to Day 57|Temperature, Vital signs, From Baseline to Day 57 | Secondary: Pharmacokinetics (PK): Cmax of HS-20094, PK: Cmax of HS-20094, Baseline to Day 57|Pharmacokinetics (PK): Tmax of HS-20094, PK: Tmax of HS-20094, Baseline to Day 57|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of HS-20094, PK: AUC of HS-20094, Baseline to Day 57|Pharmacodynamics (PD): HbA1c, PD: change of HbA1c, Baseline to Day 29
|
